Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis

Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

(2015) Yanli Zhuang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Biology and Medical Implications of Interleukin-6

(2014) T. Tanaka et al.   Cancer Immunology Research

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

(2013) Tom W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6

(2013) K K Machavaram et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein-Cholesterol Reduction in Patients with Primary Hyperlipidaemia

(2011) Jimyon Kim et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

(2011) Masahiko Mihara et al.   CLINICAL SCIENCE

Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture

(2011) L. J. Dickmann et al.   DRUG METABOLISM AND DISPOSITION

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis

(2010) Srinivasan Srirangan et al.   Therapeutic Advances in Musculoskeletal Disease

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required

(2008) H. Robert Superko et al.   CIRCULATION